Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience announced the publication of preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, in the journal Cancer Immunology Research. The study highlights ATOR-4066’s potential to activate immune responses within tumors while sparing healthy tissues, outperform existing therapies, and synergize with anti-PD-1 treatments. This development underscores Alligator’s innovative platform and strengthens its position in developing tumor-targeted therapies, offering new therapeutic strategies for CEACAM5-expressing tumors.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, an immuno-oncology approach designed to prime T cells and counteract the immunosuppressive nature of the tumor microenvironment. Alligator’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development, having shown promising results in metastatic pancreatic cancer patients.
Average Trading Volume: 492,632
Technical Sentiment Signal: Sell
Current Market Cap: SEK170.2M
See more data about ATORX stock on TipRanks’ Stock Analysis page.